论文部分内容阅读
门冬酰胺酶包括大肠杆菌和欧文菌来源的门冬酰胺酶，以及培门冬酶。与前二者相比，由于培门冬酶具有体内半衰期更长、免疫原性更低的优势，目前已成为儿童急性淋巴细胞白血病(ALL)的首选治疗药物。但是，临床应用培门冬酶治疗ALL患儿过程中，可发生培门冬酶静默失活，从而导致ALL患儿治疗无效，并且严重影响其预后。培门冬酶静默失活虽然属于亚临床超敏反应，但是与超敏反应相比，其具有一定的隐蔽性，临床难以识别。因此，笔者通过介绍在儿童ALL治疗中培门冬酶静默失活的定义、发生机制、流行病学特征、危害及处理措施等方面的最新研究进展，以期探寻培门冬酶静默失活的有效识别方法及处理措施。“,”Asparaginases include asparaginase derived from n Escherichia coli or n carotovora, and pegasparaginase. Compared with the former two, pegasparaginase has the advantages of longer half-life n in vivo and lower immunogenicity, so it has become the first choice for the treatment of acute lymphoblastic leukemia (ALL) in children.However, during the clinical application of pegasparaginase to treat children with ALL, silent inactivation of pegasparaginase may occur, which leads to ineffective treatment of ALL children, and affects their prognosis seriously.Although the silent inactivation of pegasparaginase is a subclinical hypersensitivity reaction, compared with hypersensitivity, it has a certain degree of concealment, which is hard to identify.This article introduces the latest research progress in the definition, mechanism, epidemiological characteristics, hazards and treatment measures of silent inactivation of pegasparaginase in the treatment of ALL in children, in order to find effective methods to identify and treat silent inactivation of pegasparaginase.n